[{"arm_notes": "", "treatment_id": null, "treatment_name": "This is a cluster randomized placebo-controlled trial of household contacts of laboratory-confirmed cases of COVID-19 compared to an uninfected control group of household contacts. Participants; investigators; and outcome assessors will be blind to allocation. The placebo and BioBlock sprays will be blinded at the site of manufacture. At a minimum; enrolled household cases and contacts will complete data and specimen collection at enrollment (Day 1) and for 14 days of follow-up; with at least two follow-up visits interviews for household contacts and three follow-up visits for index cases. Household (index case and household contacts) respiratory samples will be collected for SARS-CoV-2 RNA testing at 1 and 14 days. Questionnaires will be completed by Index cases at 1; 7; 14; and 21 days and by SARS-CoV-2 PCR negative household contacts at 1; 7; 14 days.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Nasal spray;248 household contacts and 124 SARS-CoV-2 positive index patients ", "treatment_id": 313, "treatment_name": "Colostrum sars-cov-2 antiviral antibodies", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "Nasal spray;248 household contacts and 124 SARS-CoV-2 positive index patients ", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]